Abstract
We report the case of a 60 year old male who complained of headache and blurry vision—that progressed to left ophthalmoplegia and ptosis—after receiving a dose of leuprolide for Prostate cancer therapy. Imaging showed a hemorrhagic sellar mass. The patient underwent transsphenoidal debulking, and the tissue obtained demonstrated immunohistochemical staining for LH. A literature review revealed nine previously reported cases of pituitary apoplexy after GnRH agonist therapy for prostate cancer. In most cases, the sellar tissues stained for LH, consistent with a gonadotropinoma. The pathophysiology of these events is unclear, but recent animal models suggest possible explanations. The predominance of gonadotropinomas is important because they do not usually present with hypersecretory symptoms. Particular attention to clinical findings suggestive of a non functioning pituitary tumor in patients receiving GnRH agonist therapy is critical as routine screening with MRI is not practical.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Cancer Society Cancer Facts & Figures 2007 (2007) Atlanta: American Cancer Society, 2007, downloaded from http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf on October 2007
Brawer M (2004) Androgen deprivation therapy: a cornerstone in the treatment of advanced prostate cancer. Rev Urol 66(Suppl 8):S3–S9
Brawer M et al (2001) Androgen deprivation and other treatments for advanced prostate cancer. Rev Urol 3(Suppl 2):S59–S68
Plosker G et al (1994) Leuprorelin. Drugs 48(6):930–967
Periti P et al (2002) Clinical Pharmacokinetics of Depot Leuprorelin. Clin Pharmacokinet 41(7):485–504
Brougham M, Heusner AP, Adams R (1950) Acute degenerative changes in adenomas of the pituitary body-with special reference to pituitary apoplexy. J Neurosurg 7:421–439
Davis A, Goel S, Picolos M et al (2006) Pituitary apoplexy after leuprolide. Pituitary 9:263–265
Ando S, Hoshino T, Mihara S (1995) Pituitary apoplexy after goserelin. Lancet 345:458
Chanson P, Schaison G (1995) Pituitary apoplexy caused by GNRH-agonist treatment revealing Gonadotroph Adenoma. J Clin Endocrinol Metab 80(7):2267–2268
Morsi A, Jamal S, Silverber J (1996) Pituitary apoplexy after leuprolide administration for carcinoma of the prostate. Clin Endocrinol 44:121–124
Reznik Y, Chapon F, Lahlou N et al (1997) Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer. J Endocrinol Invest 20:566–568
Eaton H, Phillips P, Hanieh A et al (2001) Rapid onset of pituitary apoplexy after goserelin implant for prostate cancer: need for heightened awareness. Intern Med J 20:313–314
Hernandez Morin N, Huet D, Hautecouverture M (2003) Deux cas de macroadenomes gonadotropes silencieux Ann. Endocrinol 64(3):227–231
Blaut K, Wisniewski P, Syrenicz A (2006) Apoplexy of clinically silent pituitary adenoma during prostate cancer treatment with LHRH analog. Neuro Endocrinol Lett 27(5):569–572
Hands K, Alvarez A, Bruder J (2007) Gonadotropin-releasing hormone agonist-induced pituitary apoplexy in treatment of prostate cancer: case report and review of literature. Endocr Pract 13:642–646
Engel G, Huston M, Oshima S (2003) Pituitary apoplexy after leuprolide injection for ovum donation. J Adolesc Health 32:89–93
Randeva HS et al (1999) Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol 51:181–188
Nawar R, AbdelMannan D, Selman W, Arafah B (2008) Pituitary tumor apoplexy: a review. J Intensive Care Med 23(2):75–90
Fraioli B, Esposito V, Palma L, Cantore G (1990) Hemorrhagic pituitary adenomas: clinicopathological features and surgical treatment (+ comment). Neurosurgery 27(5):741–748
Kruse A, Astrup J, Cold G, Hansen H (1992) Pressure and blood flow in pituitary adenomas measured during transphenoidal surgery. Br J Neurosurg 6:333–342
Lees P, Fahlbusch R, Zrinzo A, Pickard J (1994) Intrasellar pituitary tissue pressure, tumour size and endocrine status: an international comparison in 107 patients. Br J Neurosurg 8:313–318
Arafah B, Prunty D, Ybarra J, Hlavin M, Selman W (2000) The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia and headaches in patients with pituitary adenomas. J Clin Endocrinol Metab 85(5):1789–1793
Kovacs K, Horvath E (1973) Vascular alterations in adenomas of human pituitary glands. Angiologica 10:299–309
Schechter J (1972) Ultrastructural changes in the capillary bed of human pituitary tumors. Am J Pathol 67(1):109–118
Hirano A, Tomiyasu U, Zimmerman H (1972) The fine structure of blood vessels in chromophobe adenoma. Acta Neuropath (Berl.) 22:200–207
Kitahara K, Sakai Y, Hosaka M et al (2007) Effects of a depot formulation of the GnRH agonist leuprorelin on the ultrastructure of male rat pituitary donadotropes. Arch Histol Cytol 70(2):79–93
Massoud W, Paparel P, Lopez J et al (2006) Discovery of a pituitary adenoma following a gonadotropin releasing hormone agonist in a patient with prostate cancer. Int J Urol 13:303–304
Schuval B, Kirschenbaum A, Wolfe D, Post K, Levine A (1996) Lack of effect of a gonadotropin releasing hormone agonist in a patient with prostate cancer and a gonadotroph adenoma. J Clin Endocrinol Metab 81(2):864
Boute D, Dewailly D, Lemaire C, Christiaens J, Mazzuca M, Fossati P (1991) Effects of a long acting GnRH agonist on clinically non functioning pituitary adenomas. 5th European Workshop on Pituitary Adenoma, Venice, March 1991
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guerra, Y., Lacuesta, E., Marquez, F. et al. Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer. Pituitary 13, 54–59 (2010). https://doi.org/10.1007/s11102-009-0202-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-009-0202-2